SEOM Clinical Guideline on Hereditary Colorectal Cancer (2019)

Overview

Journal Clin Transl Oncol

Specialty Oncology

Date 2020 Jan 26

PMID 31981079

Citations 7

Authors

C Guillen-Ponce

E Lastra

I Lorenzo-Lorenzo

T Martin Gomez

R Morales Chamorro

A B Sanchez-Heras

R Serrano

M C Soriano Rodriguez

J L Soto

L Robles

Affiliations

Soon will be listed here.

Abstract

In the last 2 decades, clinical genetics on hereditary colorectal syndromes has shifted from just a molecular characterization of the different syndromes to the estimation of the individual risk of cancer and appropriate risk reduction strategies. In the last years, new specific therapies for some subgroups of patients have emerged as very effective alternatives. At the same time, germline multigene panel testing by next-generation sequencing (NGS) technology has become the new gold standard for molecular genetics.

Citing Articles

Variant Characterization of a Representative Large Pedigree Suggests "Variant Risk Clusters" Convey Varying Predisposition of Risk to Lynch Syndrome.

Barbirou M, Miller A, Mezlini A, Bouhaouala-Zahar B, Tonellato P Cancers (Basel). 2023; 15(16).

PMID: 37627102 PMC: 10452890. DOI: 10.3390/cancers15164074.

Opportunistic genetic screening increases the diagnostic yield and is medically valuable for care of patients and their relatives with hereditary cancer.

Fernandez-Castillejo S, Roig B, Mele M, Serrano S, Salvat M, Querol M J Med Genet. 2023; 61(1):69-77.

PMID: 37591735 PMC: 10803988. DOI: 10.1136/jmg-2023-109389.

Assessing the methodological strengths and limitations of the Spanish Society of Medical Oncology (SEOM) guidelines: a critical appraisal using AGREE II and AGREE-REX tool.

Santero M, de Mas J, Rifa B, Clavero I, Rexach I, Bonfill Cosp X Clin Transl Oncol. 2023; 26(1):85-97.

PMID: 37368198 PMC: 10761528. DOI: 10.1007/s12094-023-03219-0.

Lynch syndrome: from detection to treatment.

Williams M, Hadjinicolaou A, Norton B, Kader R, Lovat L Front Oncol. 2023; 13:1166238.

PMID: 37197422 PMC: 10183578. DOI: 10.3389/fonc.2023.1166238.

Increased Co-Occurrence of Pathogenic Variants in Hereditary Breast and Ovarian Cancer and Lynch Syndromes: A Consequence of Multigene Panel Genetic Testing?.

Infante M, Arranz-Ledo M, Lastra E, Abella L, Ferreira R, Orozco M Int J Mol Sci. 2022; 23(19).

PMID: 36232793 PMC: 9570103. DOI: 10.3390/ijms231911499.

References

Watkins J, Yang E, Muto M, Feltmate C, Berkowitz R, Horowitz N . Universal Screening for Mismatch-Repair Deficiency in Endometrial Cancers to Identify Patients With Lynch Syndrome and Lynch-like Syndrome. Int J Gynecol Pathol. 2016; 36(2):115-127. DOI: 10.1097/PGP.0000000000000312. View

van Leerdam M, Roos V, van Hooft J, Dekker E, Jover R, Kaminski M . Endoscopic management of polyposis syndromes: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy. 2019; 51(9):877-895. DOI: 10.1055/a-0965-0605. View

Pilarski R . Hamartoma Tumor Syndrome: A Clinical Overview. Cancers (Basel). 2019; 11(6). PMC: 6627214. DOI: 10.3390/cancers11060844. View

Herzig D, Hardiman K, Weiser M, You N, Paquette I, Feingold D . The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Inherited Polyposis Syndromes. Dis Colon Rectum. 2017; 60(9):881-894. PMC: 5701653. DOI: 10.1097/DCR.0000000000000912. View

Kastrinos F, Uno H, Ukaegbu C, Alvero C, McFarland A, Yurgelun M . Development and Validation of the PREMM Model for Comprehensive Risk Assessment of Lynch Syndrome. J Clin Oncol. 2017; 35(19):2165-2172. PMC: 5493047. DOI: 10.1200/JCO.2016.69.6120. View

Boland C, Lynch H . The history of Lynch syndrome. Fam Cancer. 2013; 12(2):145-57. PMC: 3720817. DOI: 10.1007/s10689-013-9637-8. View

Win A, Jenkins M, Dowty J, Antoniou A, Lee A, Giles G . Prevalence and Penetrance of Major Genes and Polygenes for Colorectal Cancer. Cancer Epidemiol Biomarkers Prev. 2016; 26(3):404-412. PMC: 5336409. DOI: 10.1158/1055-9965.EPI-16-0693. View

Stanich P, Pearlman R, Hinton A, Gutierrez S, LaDuca H, Hampel H . Prevalence of Germline Mutations in Polyposis and Colorectal Cancer-Associated Genes in Patients With Multiple Colorectal Polyps. Clin Gastroenterol Hepatol. 2018; 17(10):2008-2015.e3. DOI: 10.1016/j.cgh.2018.12.008. View

Buchanan D, Tan Y, Walsh M, Clendenning M, Metcalf A, Ferguson K . Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing. J Clin Oncol. 2013; 32(2):90-100. PMC: 4876359. DOI: 10.1200/JCO.2013.51.2129. View

10.

Hampel H, Pearlman R, Beightol M, Zhao W, Jones D, Frankel W . Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer. JAMA Oncol. 2018; 4(6):806-813. PMC: 5885168. DOI: 10.1001/jamaoncol.2018.0104. View

11.

Goverde A, Spaander M, van Doorn H, Dubbink H, Van Den Ouweland A, Tops C . Cost-effectiveness of routine screening for Lynch syndrome in endometrial cancer patients up to 70years of age. Gynecol Oncol. 2016; 143(3):453-459. DOI: 10.1016/j.ygyno.2016.10.008. View

12.

Baglietto L, Lindor N, Dowty J, White D, Wagner A, Gomez Garcia E . Risks of Lynch syndrome cancers for MSH6 mutation carriers. J Natl Cancer Inst. 2009; 102(3):193-201. PMC: 2815724. DOI: 10.1093/jnci/djp473. View

13.

Leenen C, Goverde A, de Bekker-Grob E, Wagner A, van Lier M, Spaander M . Cost-effectiveness of routine screening for Lynch syndrome in colorectal cancer patients up to 70 years of age. Genet Med. 2016; 18(10):966-73. DOI: 10.1038/gim.2015.206. View

14.

Sargent D, Marsoni S, Monges G, Thibodeau S, Labianca R, Hamilton S . Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010; 28(20):3219-26. PMC: 2903323. DOI: 10.1200/JCO.2009.27.1825. View

15.

Stjepanovic N, Moreira L, Carneiro F, Balaguer F, Cervantes A, Balmana J . Hereditary gastrointestinal cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019; 30(10):1558-1571. DOI: 10.1093/annonc/mdz233. View

16.

Ten Broeke S, van der Klift H, Tops C, Aretz S, Bernstein I, Buchanan D . Cancer Risks for PMS2-Associated Lynch Syndrome. J Clin Oncol. 2018; 36(29):2961-2968. PMC: 6349460. DOI: 10.1200/JCO.2018.78.4777. View

17.

Zaanan A, Shi Q, Taieb J, Alberts S, Meyers J, Smyrk T . Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials. JAMA Oncol. 2017; 4(3):379-383. PMC: 5784452. DOI: 10.1001/jamaoncol.2017.2899. View

18.

Guyatt G, Oxman A, Vist G, Kunz R, Falck-Ytter Y, Alonso-Coello P . GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008; 336(7650):924-6. PMC: 2335261. DOI: 10.1136/bmj.39489.470347.AD. View

19.

Lynch H, Snyder C, Shaw T, Heinen C, Hitchins M . Milestones of Lynch syndrome: 1895-2015. Nat Rev Cancer. 2015; 15(3):181-94. DOI: 10.1038/nrc3878. View

20.

Seifert B, McGlaughon J, Jackson S, Ritter D, Roberts M, Schmidt R . Determining the clinical validity of hereditary colorectal cancer and polyposis susceptibility genes using the Clinical Genome Resource Clinical Validity Framework. Genet Med. 2018; 21(7):1507-1516. PMC: 6579719. DOI: 10.1038/s41436-018-0373-1. View